

Nanopuff: A New Class RNA Therapeutic Carrier

Polydopamine-based carrier system offers a safe, simple, and stable method for delivering RNA therapeutics to treat cancers, infectious diseases, and neurological disorders without the toxicity of traditional nanoparticles.

Researchers at Purdue University have developed an effective carrier system for RNA drugs. Labeled "Nanopuff," this technology helps deliver RNA therapeutics to target cells via systemic administration to treat cancers, infectious diseases, and neurological disorders. Currently lipid and cationic nanoparticles are used as delivery systems for RNA, but their weaknesses are the limited control of biodistribution and the potential toxicity due to the positive charge. They also require complex preparation procedures.

Unlike the lipid and cationic nanoparticles, Nanopuff is made of polydopamine, which brings no positive charges. Nanopuff promotes ease of preparation and fulfills the unmet need for efficient RNA delivery. The technology alleviates safety concerns attributed to traditional cationic carriers and protects RNA from its harsh physiological environment. Nanopuff also enhances cellular uptake and avoids toxicity. It can be implemented as a simple, efficacious pharmacological treatment in a variety of areas, ranging from infectious diseases to cancer.

Technology Validation:

The optimal condition for siRNA binding to polydopamine was determined. The optimized form of Nanopuff showed a slightly negative charge and a z-average of 100 nm and protected siRNA from the RNase.

Advantages:

- Ease of use
- Enhanced safety profile
- Versatile

Technology ID

2023-YEO-70458

Category

Biotechnology & Life Sciences/Cell & Gene Therapy Platforms
Materials Science & Nanotechnology/Nanomaterials & Nanostructures
Pharmaceuticals/Drug Delivery & Formulations

Authors

Woojun Kim
Yoon Yeo

Further information

Joe Kasper
JKKasper@prf.org

Nathan Smith
nesmith@prf.org

View online



Applications:

- Pharmacology
- Infectious disease
- Neurological and cancer treatments

TRL: 2**Intellectual Property:**

Provisional-Gov. Funding, 2023-10-16, United States | PCT-Gov. Funding,
2024-10-15, WO